Cargando…
A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure
A first-in-human, phase 1, double blind, placebo-controlled, single ascending dose study examined the safety, tolerability, and exploratory efficacy of intravenous infusion of a recombinant growth factor, cimaglermin alfa, in patients with heart failure and left ventricular systolic dysfunction (LVS...
Autores principales: | Lenihan, Daniel J., Anderson, Sarah A., Lenneman, Carrie Geisberg, Brittain, Evan, Muldowney, James A.S., Mendes, Lisa, Zhao, Ping Z., Iaci, Jennifer, Frohwein, Stephen, Zolty, Ronald, Eisen, Andrew, Sawyer, Douglas B., Caggiano, Anthony O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113538/ https://www.ncbi.nlm.nih.gov/pubmed/30167542 http://dx.doi.org/10.1016/j.jacbts.2016.09.005 |
Ejemplares similares
-
Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials
por: Longo, DM, et al.
Publicado: (2017) -
An optimized dosing regimen of cimaglermin (neuregulin 1β3, glial growth factor 2) enhances molecular markers of neuroplasticity and functional recovery after permanent ischemic stroke in rats
por: Iaci, Jennifer F., et al.
Publicado: (2015) -
Intravenous Glial Growth Factor 2 (GGF2) Isoform of Neuregulin-1β Improves Left Ventricular Function, Gene and Protein Expression in Rats after Myocardial Infarction
por: Hill, Michael F., et al.
Publicado: (2013) -
Anti‐Remodeling and Anti‐Fibrotic Effects of the Neuregulin‐1β Glial Growth Factor 2 in a Large Animal Model of Heart Failure
por: Galindo, Cristi L., et al.
Publicado: (2014) -
Systolic stretching of the ascending aorta
por: Plonek, Tomasz, et al.
Publicado: (2019)